New drug superior to tamoxifen in blocking return of breast cancer

12/10/2004 | Wall Street Journal, The

AstraZeneca's Arimidex has shown in trials it does a much better job of preventing the recurrence of breast cancer than the popular tamoxifen, according to a study in the journal Lancet. The study, funded by AstraZeneca, said Arimidex could defend against up to 80% of the most common types of tumors that occur after menopause, compared with a 50% rate attributed to tamoxifen.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC